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There’s an old chemistry joke, based on the ortho, meta and
para nomenclature for substituents attached to a benzene
ring, that goes like this:
OK, I know it’s not very funny, but how many funny
chemistry jokes are there? Anyway, someone reminded me
of this joke the other day and while I was busy not laughing I
was also thinking about something else. Because these days,
for most people in the life sciences, and I bet nearly every-
body in genome biology, the prefix meta doesn’t conjure up
images of di-substituted benzene. It calls to mind the meta-
analysis of data.
Meta-analysis - sometimes contracted to metanalysis - is one
of those Sudoku-like fads that seem to pop up overnight and
sweep the entire country in about as little time. ‘Metanalysis’
doesn’t mean the same thing to scientists as it does to other
academics. In linguistics, metanalysis is the act of breaking
down a word or phrase into segments or meanings not
original to it. The term was coined by the linguist Otto
Jespersen, and comes from the Greek for ‘a change of
breakdown’. Here’s an example, courtesy of Wikipedia: in
the phrase “God rest ye merry gentlemen”, originally merry
was a complement with rest (as in “God rest ye merry,
gentlemen” - note the position of the comma - that is, “[may
God] give you gentlemen a pleasant repose”). But now, by a
process of metanalysis, merry is frequently construed as an
ordinary adjective modifying gentlemen (“God rest ye, merry
gentlemen”) - and in all probability it can be relexicalized
with the current sense of merry, that is, cheerful, jolly,
though that is harder to be certain of. (The expression “to
rest merry” and the like was once generally current, by the
way.) Incidentally, I love this sort of thing, but it isn’t what
‘meta-analysis’ means in biomedical research.
Meta-analysis for us is a technique whereby all data from all
available studies of something are combined, often regard-
less of the relative quality of the data. The method is used by
researchers to get a maximum amount of statistical
information from a set of studies that might not have large
enough individual sample sizes, or whose results may be of
marginal statistical significance.
In a typical meta-analysis, the results of, say, four different
clinical trials of a drug, or the data from five independent
studies of the association of a genetic variation with a particular
disease, are merged into a single statistical sample. The sample
is then analyzed for the same correlation, or lack thereof.
I don’t know where it the practice came from but it’s of
relatively recent origin - the late 1970s or so. Certainly when
I was a student there wasn’t an entire subfield devoted to
pooling studies and reinterpreting the results. But the
medical literature, and the literature of human genetics, is
awash with it now.
Imagine the excitement of the person who thought this up.
“Omigod! I can take other people’s results, throw them
together, and come up with a conclusion that in some cases
will horrify them, and I can get it published in good journals -
sometimes with quite high visibility if the data concern an
important human disease or a dietary substance that’s
popular - and I don’t have to do any of the really hard work!
I don’t have to actually do the studies. I don’t have to find
the patients, or collect the questionnaires, or analyze the
genomes, or any of that difficult, real science. They’ll do it for
me, and then I can use their data for my own benefit. This is
like making money with other people’s money! This is how
the first banker must have felt!!”
I am not a professional statistician, but I have taught statistics,
and as a protein crystallographer I have to be familiar with
most of the rudimentary forms of statistical analysis of data.
And everything I know about the subject suggests to me that
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MDmeta-analysis could lead to all kinds of trouble. One of the
things I’ve learned is that you don’t improve bad data by
combining it with good data. In fact, exactly the opposite
occurs: the bad data degrade the better. “When in doubt,
leave it out” is what I usually tell my students - occasionally
modified to “when in doubt, weight it down”. But most meta-
analyses don’t apply relative weights to the studies they
combine (it’s pretty hard to see where they would get the
weights anyway), so studies of all sorts of varying quality are
sometimes pooled as though they were equally reliable.
And even if we allow that the people who do this may get
better statistical precision this way, owing to an enlargement
of the sample size, I don’t think statistical precision is the
issue here. Adding more data may reduce the random errors,
but I believe that in most biomedical and genomics studies -
especially the latter - the real importance may lie in the
systematic errors, or, more precisely (pun intended), the
systematic differences.
Meta-analysts justify combining data from different studies
in part because doing the same experiment in different ways
has long been a way to avoid problems caused by non-
random or systematic errors. And it is true that using multiple
studies that involve different questions or different experi-
mental techniques, with different patient populations and
other variations, may allow global trends to emerge from
underneath spikes of systematic differences. But there is a
danger there. The first meta-analysis I ever encountered,
some years ago, concerned a gene I was interested in. It had
been reported that a particular polymorphism in this gene
was associated with a reduction in risk for certain diseases in
the Han Chinese population. Several other studies, including
some with much smaller sample sizes, had looked for a
disease association in other ethnic groups but had failed to
find any. The meta-analysis pooled all of these studies and
concluded, rather definitively, that the particular variant did
not confer a change in risk for any of the diseases in
question. And their overall statistics certainly bore that out.
There was just one problem: I had read the original Han
Chinese study rather carefully, and the work was well done,
and the statistical correlation with disease risk was
absolutely significant. But if you only read the meta-analysis -
and I’ve seen that referred to repeatedly since and even
quoted from at meetings - you wouldn’t know that.
Because in the age of genomics, it’s not about the general
population anymore. Personalized medicine is coming, and
our studies of haplotypes and other natural variations make
it clear that, even if we can’t quite get down to the level of the
individual yet in all studies, the genetic (and environmental)
background of the population being evaluated can make a
huge difference. Ethnic and geographical differences aren’t
not systematic errors to be averaged out; they’re essential
components of the ways genes (or drugs, or nutrients)
interact with the human body. The right question to be
asking in the case of the study I referred to is not whether
the polymorphism alters disease risk in the general population,
but rather why it does so in the Han Chinese population.
What are the particular combinations of other genetic and
environmental factors that cause this variant to become
associated with a set of diseases? That’s where the really
interesting science, and medicine, lies. Average different
studies together willy-nilly and you run the risk that some-
times you may average out precisely the those variations that
provide the clues we are looking for as to how human health
really works.
Now you may think that this column is all about trashing
meta-analysis, and, to be honest, it started out that way. But
then I had a discussion with David Altshuler, a human
geneticist at Harvard Medical School and the Broad Institute
at MIT, that made me rethink what was about to become a
blanket condemnation. He pointed out to me another goal of
meta-analysis in current human genetic studies. The key
issues, as he put it, are first, the different statistical thresholds
needed in discovery science with a low prior (as compared
with hypothesis testing in a well-established field), and
second, in human genetics the ability to use the rest of the
genome as independent tests to assess the matching of cases
and controls in human genetics.
Here’s how he explained the first issue: in genetic mapping
with the goal of initially determining which genes might
actually play a role in human disease, there is a very low a
priori probability of any variant being associated with any
risk (on the order of one in a million), and - that is, with an
initial goal of determining which genes might actually play a
role in human disease risk - one can’t say that a p value of
0.01 or even 0.0001 is ‘absolutely significant’. He’s right:
most findings of that magnitude turn out to be entirely
irreproducible, and are likely to be false positives. But
finding consistent results by meta-analysis increases evi-
dence that the null hypothesis is wrong - and confidence that
there is a relationship between the variant and risk. Without
that confidence, he asserts, the field was awash with wishful
thinking about lots of candidate genes that reductionist
biologists had found in cells and in animal models, and
wanted to believe were ‘genetically validated in people’ - but
that turned out to be noise.
If you look into it, you will find that there is a long history in
genetic mapping of setting the right threshold based on the
number of tests. In linkage mapping, the LOD score that
indicated linkage between a gene variant and a trait was 3.0 -
not p < 0.05 (LOD stands for logarithm to the base 10 of
odds; a LOD score of 3.0 means the likelihood of observing
the given pedigree if two loci are not linked is less than 1 in
1000). By contrast, in genome-wide human genetic studies,
a p of less than or equal to 0.0000001 is typically required
for proof of association of a gene with a trait. And while
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one I mentioned above it is more like p < 0.05, that threshold
has a history of not always supporting reproducible
discoveries. It is in gathering enough data to really get the
confidence level to where it needs to be that meta-analysis
has proven proved valuable in many cases.
The second issue is the quality of the data that goes into
meta-analysis, and the ability to compare and align it. In
most studies, Altshuler agrees with me that you can’t know if
you are washing out good data with bad. But he makes a
strong case, with which I am forced to agree, that in the
current wave of genome-wide association studies, the
studies often use the same phenotype definition, or the same
microarray protocols, and so the data may well be com-
parable (clearly, it is important to see whether that is the
case, if you want to evaluate the meta-analysis critically).
When done properly, information from the rest of the
genome can be used to assess the properties of the data,
matching of cases and controls, and so on, which, as he puts
it, “can result in valid combination of lots of good data,
rather than sloppy mashing up of lots of bad data”. Finally,
sometimes you actually may want to test the hypothesis
across ethnicity or age or other variables. In those instances,
meta-analysis allows you to put the data together in a valid
way - a way that is probably better than just reading the
papers and trying to compare them.
Dr Altshuler went on to make a very valuable point, which I
think belongs in this column: he feels there that is currently
a big and unfortunate divide between cell and molecular
biologists and people using human genetics to find disease
genes. The tone of the first part of my column just reinforced
his concern, I’m sorry to say. For disease research, it’s
certainly true that knowing up front that a gene influences
the disease in humans is invaluable, and I think he’s right
that meta-analysis can be a powerful tool for getting that
correct. (As he asked me: “Would you want to do functional
work on a gene that turns out to be a false positive?”)
A final point: meta-analysis is currently being used in two
ways in human genetics, and I may have given a false
impression that there is only one. One method is when there
is a pre-existing hypothesis that needs to be tested. A good
example comes from Altshuler’s own work (Altshuler D, et
al.: Nat Genet 2000, 26:76-80). The data the authors had
collected gave a positive result, but others had claimed the
opposite. The studies were comparable enough that meta-
analysis was able to show that the data were actually
consistent and reinforced one another. In such cases meta-
analysis serves as a reality check, and helps avoid possible
bias in the selection of data that might support one hypothe-
sis or another.
But careful meta-analysis can also in some cases be
hypothesis generating, because enough studies might, as I
mentioned above, allow previously undetected signals to rise
above the noise. These can then be tested experimentally,
and of course, need to be.
Dr Altshuler closed our discussion with a nice comment:
“Meta-analysis,” he pointed out, “is just a method. Garbage
in, garbage out. But in genetic mapping of common complex
diseases, where it is clear there are many different variants
contributing, and where studies are expensive, combining
data to learn the most is well justified and valid.”
It is true that it’s often the original studies that matter, that
data need to be examined carefully, and that a study ideally
must be accepted or rejected on its own merits. People are
fond of saying that the devil is in the details. But God is in
the details too. In the age of genomics, the details are
ultimately what matter: the complex interplay of individual
gene and genetic background, diet, environment, perhaps
even state of mind, is what determines whether we are prone
to this disease or that, react poorly or well to this drug or
that, age well or badly. Meta-analysis can hide those details,
but used properly, it can also be revealing. I guess you could
say that writing this column has led to a meta-morphosis in
the way I think about this subject, and that I have to back
away from my meta-phor about making money with other
people’s money. In the right hands, meta-analysis can be a
valuable tool, which is a pity, because it’s so much more fun
to write a column that completely trashes something. Meta-
physically speaking, of course.
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